Financhill
Buy
56

PHR Quote, Financials, Valuation and Earnings

Last price:
$24.96
Seasonality move :
10.46%
Day range:
$24.46 - $25.08
52-week range:
$17.07 - $30.53
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.41x
P/B ratio:
5.52x
Volume:
268.1K
Avg. volume:
514.4K
1-year change:
19.29%
Market cap:
$1.5B
Revenue:
$419.8M
EPS (TTM):
-$1.02

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
PHR
Phreesia
$115M $0.16 13.88% -91.79% $31.77
AMS
American Shared Hospital Services
$8.6M $0.04 18.76% -92.73% $4.84
CCEL
Cryo-Cell International
$7.9M $0.01 -0.02% -62.5% $8.50
EVH
Evolent Health
$460.3M $0.09 -28.07% -- $15.15
OMCL
Omnicell
$260M $0.20 5.71% 249.27% $50.71
PINC
Premier
$242.1M $0.30 -27.06% -31.77% $19.79
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
PHR
Phreesia
$24.86 $31.77 $1.5B -- $0.00 0% 3.41x
AMS
American Shared Hospital Services
$2.73 $4.84 $17.6M 8.03x $0.00 0% 0.65x
CCEL
Cryo-Cell International
$5.52 $8.50 $44.6M 552.00x $0.25 9.06% 1.41x
EVH
Evolent Health
$9.84 $15.15 $1.1B -- $0.00 0% 0.44x
OMCL
Omnicell
$31.40 $50.71 $1.5B 116.30x $0.00 0% 1.31x
PINC
Premier
$20.39 $19.79 $1.9B 14.37x $0.21 4.12% 1.78x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
PHR
Phreesia
0.73% 1.210 0.12% 1.64x
AMS
American Shared Hospital Services
45.9% 0.382 90.05% 1.35x
CCEL
Cryo-Cell International
-796.74% 1.052 20.39% 0.49x
EVH
Evolent Health
39.8% -1.253 51.15% 0.73x
OMCL
Omnicell
21.51% 1.628 16.5% 1.07x
PINC
Premier
8.08% 0.697 7.77% 0.73x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
PHR
Phreesia
$76.1M -$7.6M -22.86% -22.95% -4.37% $9.2M
AMS
American Shared Hospital Services
$1.4M -$553K 8.36% 13.75% -3.47% -$407K
CCEL
Cryo-Cell International
$6M $1.1M 122.88% -- 12.91% $892K
EVH
Evolent Health
$75.7M -$1.3M -3.73% -5.92% -2.66% -$32.4M
OMCL
Omnicell
$141.8M $12.4M 0.72% 1.04% 4.04% $42.7M
PINC
Premier
$171.2M -$92.8M -0.23% -0.24% -38.63% $89.5M

Phreesia vs. Competitors

  • Which has Higher Returns PHR or AMS?

    American Shared Hospital Services has a net margin of -5.83% compared to Phreesia's net margin of -2.96%. Phreesia's return on equity of -22.95% beat American Shared Hospital Services's return on equity of 13.75%.

    Company Gross Margin Earnings Per Share Invested Capital
    PHR
    Phreesia
    69.4% -$0.11 $266.7M
    AMS
    American Shared Hospital Services
    19.57% -$0.03 $54.2M
  • What do Analysts Say About PHR or AMS?

    Phreesia has a consensus price target of $31.77, signalling upside risk potential of 27.79%. On the other hand American Shared Hospital Services has an analysts' consensus of $4.84 which suggests that it could grow by 77.29%. Given that American Shared Hospital Services has higher upside potential than Phreesia, analysts believe American Shared Hospital Services is more attractive than Phreesia.

    Company Buy Ratings Hold Ratings Sell Ratings
    PHR
    Phreesia
    9 0 0
    AMS
    American Shared Hospital Services
    0 0 0
  • Is PHR or AMS More Risky?

    Phreesia has a beta of 0.823, which suggesting that the stock is 17.706% less volatile than S&P 500. In comparison American Shared Hospital Services has a beta of 0.424, suggesting its less volatile than the S&P 500 by 57.593%.

  • Which is a Better Dividend Stock PHR or AMS?

    Phreesia has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. American Shared Hospital Services offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Phreesia pays -- of its earnings as a dividend. American Shared Hospital Services pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PHR or AMS?

    Phreesia quarterly revenues are $109.7M, which are larger than American Shared Hospital Services quarterly revenues of $7M. Phreesia's net income of -$6.4M is lower than American Shared Hospital Services's net income of -$207K. Notably, Phreesia's price-to-earnings ratio is -- while American Shared Hospital Services's PE ratio is 8.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phreesia is 3.41x versus 0.65x for American Shared Hospital Services. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PHR
    Phreesia
    3.41x -- $109.7M -$6.4M
    AMS
    American Shared Hospital Services
    0.65x 8.03x $7M -$207K
  • Which has Higher Returns PHR or CCEL?

    Cryo-Cell International has a net margin of -5.83% compared to Phreesia's net margin of 3.55%. Phreesia's return on equity of -22.95% beat Cryo-Cell International's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    PHR
    Phreesia
    69.4% -$0.11 $266.7M
    CCEL
    Cryo-Cell International
    75.1% $0.03 -$1.6M
  • What do Analysts Say About PHR or CCEL?

    Phreesia has a consensus price target of $31.77, signalling upside risk potential of 27.79%. On the other hand Cryo-Cell International has an analysts' consensus of $8.50 which suggests that it could grow by 53.99%. Given that Cryo-Cell International has higher upside potential than Phreesia, analysts believe Cryo-Cell International is more attractive than Phreesia.

    Company Buy Ratings Hold Ratings Sell Ratings
    PHR
    Phreesia
    9 0 0
    CCEL
    Cryo-Cell International
    0 0 0
  • Is PHR or CCEL More Risky?

    Phreesia has a beta of 0.823, which suggesting that the stock is 17.706% less volatile than S&P 500. In comparison Cryo-Cell International has a beta of 0.607, suggesting its less volatile than the S&P 500 by 39.282%.

  • Which is a Better Dividend Stock PHR or CCEL?

    Phreesia has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cryo-Cell International offers a yield of 9.06% to investors and pays a quarterly dividend of $0.25 per share. Phreesia pays -- of its earnings as a dividend. Cryo-Cell International pays out 502.5% of its earnings as a dividend.

  • Which has Better Financial Ratios PHR or CCEL?

    Phreesia quarterly revenues are $109.7M, which are larger than Cryo-Cell International quarterly revenues of $8M. Phreesia's net income of -$6.4M is lower than Cryo-Cell International's net income of $282.9K. Notably, Phreesia's price-to-earnings ratio is -- while Cryo-Cell International's PE ratio is 552.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phreesia is 3.41x versus 1.41x for Cryo-Cell International. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PHR
    Phreesia
    3.41x -- $109.7M -$6.4M
    CCEL
    Cryo-Cell International
    1.41x 552.00x $8M $282.9K
  • Which has Higher Returns PHR or EVH?

    Evolent Health has a net margin of -5.83% compared to Phreesia's net margin of -3.53%. Phreesia's return on equity of -22.95% beat Evolent Health's return on equity of -5.92%.

    Company Gross Margin Earnings Per Share Invested Capital
    PHR
    Phreesia
    69.4% -$0.11 $266.7M
    EVH
    Evolent Health
    11.71% -$0.27 $1.7B
  • What do Analysts Say About PHR or EVH?

    Phreesia has a consensus price target of $31.77, signalling upside risk potential of 27.79%. On the other hand Evolent Health has an analysts' consensus of $15.15 which suggests that it could grow by 54%. Given that Evolent Health has higher upside potential than Phreesia, analysts believe Evolent Health is more attractive than Phreesia.

    Company Buy Ratings Hold Ratings Sell Ratings
    PHR
    Phreesia
    9 0 0
    EVH
    Evolent Health
    9 1 0
  • Is PHR or EVH More Risky?

    Phreesia has a beta of 0.823, which suggesting that the stock is 17.706% less volatile than S&P 500. In comparison Evolent Health has a beta of 1.199, suggesting its more volatile than the S&P 500 by 19.872%.

  • Which is a Better Dividend Stock PHR or EVH?

    Phreesia has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Evolent Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Phreesia pays -- of its earnings as a dividend. Evolent Health pays out -32.59% of its earnings as a dividend.

  • Which has Better Financial Ratios PHR or EVH?

    Phreesia quarterly revenues are $109.7M, which are smaller than Evolent Health quarterly revenues of $646.5M. Phreesia's net income of -$6.4M is higher than Evolent Health's net income of -$22.8M. Notably, Phreesia's price-to-earnings ratio is -- while Evolent Health's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phreesia is 3.41x versus 0.44x for Evolent Health. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PHR
    Phreesia
    3.41x -- $109.7M -$6.4M
    EVH
    Evolent Health
    0.44x -- $646.5M -$22.8M
  • Which has Higher Returns PHR or OMCL?

    Omnicell has a net margin of -5.83% compared to Phreesia's net margin of 5.16%. Phreesia's return on equity of -22.95% beat Omnicell's return on equity of 1.04%.

    Company Gross Margin Earnings Per Share Invested Capital
    PHR
    Phreesia
    69.4% -$0.11 $266.7M
    OMCL
    Omnicell
    46.19% $0.34 $1.6B
  • What do Analysts Say About PHR or OMCL?

    Phreesia has a consensus price target of $31.77, signalling upside risk potential of 27.79%. On the other hand Omnicell has an analysts' consensus of $50.71 which suggests that it could grow by 61.51%. Given that Omnicell has higher upside potential than Phreesia, analysts believe Omnicell is more attractive than Phreesia.

    Company Buy Ratings Hold Ratings Sell Ratings
    PHR
    Phreesia
    9 0 0
    OMCL
    Omnicell
    3 5 0
  • Is PHR or OMCL More Risky?

    Phreesia has a beta of 0.823, which suggesting that the stock is 17.706% less volatile than S&P 500. In comparison Omnicell has a beta of 0.785, suggesting its less volatile than the S&P 500 by 21.543%.

  • Which is a Better Dividend Stock PHR or OMCL?

    Phreesia has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Omnicell offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Phreesia pays -- of its earnings as a dividend. Omnicell pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PHR or OMCL?

    Phreesia quarterly revenues are $109.7M, which are smaller than Omnicell quarterly revenues of $306.9M. Phreesia's net income of -$6.4M is lower than Omnicell's net income of $15.8M. Notably, Phreesia's price-to-earnings ratio is -- while Omnicell's PE ratio is 116.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phreesia is 3.41x versus 1.31x for Omnicell. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PHR
    Phreesia
    3.41x -- $109.7M -$6.4M
    OMCL
    Omnicell
    1.31x 116.30x $306.9M $15.8M
  • Which has Higher Returns PHR or PINC?

    Premier has a net margin of -5.83% compared to Phreesia's net margin of -39.96%. Phreesia's return on equity of -22.95% beat Premier's return on equity of -0.24%.

    Company Gross Margin Earnings Per Share Invested Capital
    PHR
    Phreesia
    69.4% -$0.11 $266.7M
    PINC
    Premier
    71.26% -$1.01 $1.9B
  • What do Analysts Say About PHR or PINC?

    Phreesia has a consensus price target of $31.77, signalling upside risk potential of 27.79%. On the other hand Premier has an analysts' consensus of $19.79 which suggests that it could fall by -2.96%. Given that Phreesia has higher upside potential than Premier, analysts believe Phreesia is more attractive than Premier.

    Company Buy Ratings Hold Ratings Sell Ratings
    PHR
    Phreesia
    9 0 0
    PINC
    Premier
    0 7 0
  • Is PHR or PINC More Risky?

    Phreesia has a beta of 0.823, which suggesting that the stock is 17.706% less volatile than S&P 500. In comparison Premier has a beta of 0.516, suggesting its less volatile than the S&P 500 by 48.448%.

  • Which is a Better Dividend Stock PHR or PINC?

    Phreesia has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Premier offers a yield of 4.12% to investors and pays a quarterly dividend of $0.21 per share. Phreesia pays -- of its earnings as a dividend. Premier pays out 79.64% of its earnings as a dividend. Premier's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios PHR or PINC?

    Phreesia quarterly revenues are $109.7M, which are smaller than Premier quarterly revenues of $240.3M. Phreesia's net income of -$6.4M is higher than Premier's net income of -$96M. Notably, Phreesia's price-to-earnings ratio is -- while Premier's PE ratio is 14.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phreesia is 3.41x versus 1.78x for Premier. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PHR
    Phreesia
    3.41x -- $109.7M -$6.4M
    PINC
    Premier
    1.78x 14.37x $240.3M -$96M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Vertex Stock Still a Good Buy?
Is Vertex Stock Still a Good Buy?

Over the past ten years or so, Vertex Pharmaceuticals (NASDAQ:…

Is Okta Stock Finally Gaining Investor Confidence?
Is Okta Stock Finally Gaining Investor Confidence?

Given how digital transformation has proliferated, cyberattacks have also been…

Is The Trade Desk the Best Advertising Stock Now?
Is The Trade Desk the Best Advertising Stock Now?

The worldly backdrop is now shrouded in heavy uncertainty and…

Stock Ideas

Buy
59
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
58
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Buy
55
Is NVDA Stock a Buy?

Market Cap: $2.7T
P/E Ratio: 37x

Alerts

Buy
85
HIMS alert for Apr 30

Hims & Hers Health [HIMS] is down 5.48% over the past day.

Buy
54
EAT alert for Apr 30

Brinker International [EAT] is down 1.82% over the past day.

Sell
16
NSP alert for Apr 30

Insperity [NSP] is down 3.3% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock